Orchard Therapeutics (NASDAQ:ORTX) reported quarterly losses of $(0.04) per share. This is a 86.21 percent increase over losses of $(0.29) per share from the same period last year.
Autoimmune Disease Player Immunovant’s Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in
